CURA Share Price Performance
CA$3.16
0.79 (33.33%)
36.0% undervalued intrinsic discount
CA$4.94
Fair Value
Price CA$3.16
AnalystConsensusTarget CA$4.94
AnalystLowTarget CA$4.37
AnalystHighTarget CA$4.51
Fair ValueCA$4.94
Share Pricen/a
Curaleaf Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
CURA Community Narratives
AN
Fair Value CA$4.94 36.0% undervalued intrinsic discount
Regulatory Winds Will Drive New Industry Leadership And Outperformance Opportunities
1users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
Fair Value CA$4.37 27.6% undervalued intrinsic discount
Intensified Global Regulation Will Squeeze Cannabis Margins Despite European Hopes
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CA$4.51 29.9% undervalued intrinsic discount
Medical Cannabis Legalization And Wellness Trends Will Redefine Market Opportunities
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Intensified Global Regulation Will Squeeze Cannabis Margins Despite European Hopes
Key Takeaways Intensifying regulatory scrutiny, price compression, and new competitors threaten margins, market share, and long-term profitability. Heavy investment and macroeconomic headwinds risk ongoing negative cash flow and shrinking shareholder value.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$4.37
27.6% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
6.95% p.a.
Profit Margin
5.77%
Future PE
35.42x
Price in 2029
CA$5.32
Regulatory Winds Will Drive New Industry Leadership And Outperformance Opportunities
Key Takeaways International market growth, product innovation, and strategic R&D investments are set to diversify revenue streams and strengthen long-term growth prospects. Vertical integration, supply chain optimization, and industry consolidation are expected to boost margins, market share, and operational efficiency.Read more
364
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
CA$4.94
36.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
6.76% p.a.
Profit Margin
3.96%
Future PE
57.91x
Price in 2029
CA$6.02
Medical Cannabis Legalization And Wellness Trends Will Redefine Market Opportunities
Key Takeaways International expansion, innovation in medical devices, and proprietary brands position Curaleaf for significant gains in revenue, margin, and category leadership as global markets open. Operational efficiency, premium product offerings, and asset-light strategies underpin resilience, recurring growth, and outsized market share amid broad industry legalization and normalization.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$4.51
29.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
4.47% p.a.
Profit Margin
1.62%
Future PE
133.6x
Price in 2028
CA$5.42
Trending Discussion
Recently Updated Narratives
AN
CURA: Expanded Retail Footprint And Higher Guidance Will Support Bullish Re Rating
Fair Value: CA$4.37 27.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CURA: Regulatory Shift And Exit From Hemp Will Support Wider Moat
Fair Value: CA$4.94 36.0% undervalued intrinsic discount
16 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Medical Cannabis Legalization And Wellness Trends Will Redefine Market Opportunities
Fair Value: CA$4.51 29.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Curaleaf Holdings, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 26, 2026
- -0.19
- 48.97%
- -21.72%
- 85.2%
About CURA
- Founded
- n/a
- Employees
- 5519
- CEO
- WebsiteView website
Curaleaf Holdings, Inc. produces and distributes cannabis products in the United States and internationally. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of hemp-derived THC products through wholesale channels. The company is headquartered in Stamford, Connecticut.
